TheChek News Flow

+------------------------------------------------------------------------------+

BN 11/25 17:14 *FCC TO BOOST STAKE IN REALIA TO 36.85% FROM 30.02%

+------------------------------------------------------------------------------+

FCC to Boost Stake in Realia to 36.85% From 30.02% 2013-11-25 17:18:33.315 GMT

By Charles Penty Nov. 25 (Bloomberg) -- FCC to acquire 29.99m shares in Realia at EU1.92 p/shr, Realia says. * FCC opts to capitalize EU57.6m loan, Realia says * Sareb still hasn’t notified decision on capitalization of its loan: Realia * Realia comments in regulatory filing today

Link to Company News:{BKIA SM <Equity> CN <GO>} Link to Company News:{FCC SM <Equity> CN <GO>} Link to Company News:{RLIA SM <Equity> CN <GO>}

For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}

To contact the editor responsible for this story: Charles Penty at +34-91-700-9654 or cpenty@bloomberg.net

3 cos interested in buying Given Imaging

The asking price for the endoscopic capsule developer is reportedly $750-800 million, a 20% premium on the market cap.

Sources inform ''Globes'' that Given Imaging Ltd. (Nasdaq: GIVN; TASE: GIVN) has resumed talks, which might lead to the sale of the company, almost a year after calling them off. The developer of the PillCam endoscopic capsule for diagnosis of bowel diseases has a market cap of $675 million, following a 21% rise in its share price since the beginning of the year. The asking price reportedly reflects a company value of $750-800 million, a 20% premium on the current market cap, and the intention is to close a deal by the end of the year. The sources said that three companies are interested in acquiring Given Imaging, two as strategic investors and the third as a financial investor. Given Imaging declined to comment on the report. Over a year ago, Given Imaging confirmed that it intended to consider "strategic options" to create value for shareholders, and that talks had begun with several parties interested in acquiring the company. Potential buyers mentioned at the time included Fujifilm Holdings Corporation (TSE:4901) unit Fujinon, Johnson & Johnson (NYSE: JNJ), and Samsung Electronics Co. Ltd. (KSX: 5930; LSE: SMSN). When Given Imaging could not obtain the company value it wanted, its board of directors ended the talks. It reportedly reviewed offers at a company value of $700-750 million, but Given Imaging's controlling shareholder, Nochi Dankner's IDB Holding Corp. Ltd. (TASE:IDBH) had apparently hoped for more, possibly as much as $1 billion. After the talks were called off, Discount Investment Corporation (TASE: DISI), through which IDB controls Given Imaging, announced that it wanted to sell its 46% stake in the company (held directly and through subsidiary Elron Electronic Industries Ltd. (TASE: ELRN) and Rafael Development Corporation, Elron's joint venture with Rafael Advanced Defense Systems Ltd.). The reason for the decision was IDB's financial distress. New multibillion dollar markets Today's Given Imaging is in a different place from where it was a year ago. Since the talks for the sale of controlling interest were ended, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has approved the company's upgraded PillCam capsule and the company has obtained insurance indemnification for it. The company will able to begin sales of the upgraded capsules in early 2014, opening a market worth hundreds of millions of dollars. The company hopes to obtain US Food and Drug Administration (FDA) approval by the end of the year. US marketing approval and insurance indemnification will add another $1.7 billion market. In its full-year guidance for 2013, Given Imaging project earnings per share of $0.80-0.88 on $195-205 million revenue, although it recently said that it expects to only achieve the lower threshold of the guidance. It had $142 million in cash at the end of September.

+------------------------------------------------------------------------------+

Belarus to Earn $2b From Potash Sales This Year: Lukashenko 2013-11-25 15:50:16.948 GMT

By Aliaksandr Kudrytski Nov. 25 (Bloomberg) -- Belarus has “generally” recovered after breakup with Uralkali, President Aleksandr Lukashenko says in Minsk, according to e-mailed statement from press service. * Forecast sales for 2013 “not a bad result” given complicated potash market: Lukashenko * NOTE: Belarus received $2.7b from exporting 6.1mt of potash fertilizers last yr, according to national statistics committee * NOTE: Belarus Plans 2014 Potash Exports of 7m tons at $300/t: Interfax NSN MW94876S972K <GO> * NOTE: Belarus Cedes Uralkali’s Baumgertner to Russia After Sale Accord NSN MWML446JTSE8 <GO>

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

--Editors: Scott Rose, Torrey Clark

To contact the reporter on this story: Aliaksandr Kudrytski in Minsk, Belarus at +7-495-771-7706 or akudrytski@bloomberg.net

To contact the editor responsible for this story: Balazs Penz at +36-1-475-1191 or bpenz@bloomberg.net

+------------------------------------------------------------------------------+

BFW 11/25 15:00 *CHRYSLER IPO SAID DELAYED BY U.S. TAX UNCERTAINTY BN 11/25 15:00 *PEOPLE FAMILIAR WITH PLANNING DESCRIBE DELAY BN 11/25 15:00 *CHRYSLER IPO SAID DELAYED BY U.S. TAX UNCERTAINTY

+------------------------------------------------------------------------------+

Chrysler IPO Said Delayed by U.S. Tax Uncertainty 2013-11-25 15:03:32.318 GMT

By Brad Skillman Nov. 25 (Bloomberg) -- Chrysler IPO was delayed after automaker wasn’t able to resolve routine tax issue quickly enough to complete sale this yr, two people with knowledge of matter told Bloomberg’s Tommaso Ebhardt, Mark Clothier and David Welch. * Chrysler needs letter from IRS to clarify tax liabilities after IPO, people said * Spokesmen for Fiat, Chyrsler declined to comment * Earlier, Fiat Says Chrysler Decided to Not Proceed With IPO This Year {NSN MWTLT46JTSER <go>}

Link to Company News:{F IM <Equity> CN <GO>}

For Related News and Information: First Word scrolling panel: {FIRST<GO>} First Word newswire: {NH BFW<GO>}

To contact the editor responsible for this story: Brad Skillman at +1-212-617-2763 or bskillman1@bloomberg.net

+------------------------------------------------------------------------------+

BN 11/25 14:08 *NESTLE CAN APPEAL ONCE RULING IS PUBLISHED IN COMING WEEKS BN 11/25 14:08 *NESPRESSO SAYS PATENT WAS FOR PIXIE MACHINE BN 11/25 14:08 *NESTLE HAS NESPRESSO PATENT REVOKED BY EUROPEAN PATENT OFFICE

+------------------------------------------------------------------------------+

*NESTLE HAS NESPRESSO PATENT REVOKED BY EUROPEAN PATENT OFFICE 2013-11-25 14:09:06.765 GMT

--GELU SULUGIUC

-0- Nov/25/2013 14:09 GMT

Gapping up

In reaction to strong earnings/guidance: ENTA +2.6%.

M&A news: GA +10.5% (receives proposal from the co's Chairman to acquire the company at $11.75 per share).

Select EU financial related names showing strength: NBG +1.7%, DB +1.5%, UBS +1.4%, LYG +1%, RBS +0.7%.

Select 3-D printing names showing strength: VJET +5%, ONVO +4.9%, DDD +1.4%.

Dialysis stocks gapping up on CMS payment rate changes for end-stage renal disease facilities in 2014: FMS +7.3%, DVA +3.9%, NXTM +3.6%.

Other news: OREX +19.7% (successful results of the interim analysis of the Light Study; co will resubmit the Contrave NDA in the next few weeks), ARIA +8.7% (cont strength), GLUU +6.9% (attributed to positive blog mention making the rounds), SIRI +4.9% (positive Barron's mention), JNY +4% (Sycamore in discussions to purchase JNY for $16/share, according to reports), CYCC +3.7% (announces data safety monitoring board recommendation to continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML), ANIK +3% (to join S&P SmallCap 600), STML +2.9% (presents results of clinical trial results with a synthetic peptide vaccine for brain cancer), DAL +2.1% (still checking), YGE +2% (to supply 15 MW PV modules to Solarcentury in the UK), BBY +1.9% (ticking higher on light volume by 2% following positive mention on MadMoney), RPRX +1.2% (reports it has been granted a face to face meeting with the FDA to discuss the pivotal Androxal efficacy studies), KTOS +1% (discontinues proposed refinancing effort), YHOO +0.9% (in negotiations with Katie Couric, according to reports), ARWR +0.8% (submits application to begin Phase 2a trial of ARC-520 for the treatment of chronic hepatitis B infection).

Analyst comments: DVAX +6.2% (upgraded to Buy at MLV & Co), AA +3.8% (upgraded to Buy at Goldman), MDAS +3.5% (upgraded to Buy from Hold at KeyBanc Capital Mkts), EGHT +2.8% (initiated with Buy at Deutsche Bank, initiated with Overweight at Barclays, initiated with a Buy at BofA/Merrill), PAGP +2.7% (initiated with a Overweight at JP Morgan), CAT +1.7% (upgraded to Buy at BofA/Merrill), SYK +1.6% (upgraded to Outperform from Mkt Perform at Bernstein), UN +1.5% (upgraded to Outperform from Neutral at Exane BNP Paribas), KCG +1.2% (upgraded to Outperform from Mkt Perform at Raymond James), ATVI +1.1% (added to to Stifel Select List).

Gapping down

In reaction to disappointing earnings/guidance: QIHU -3.6%, (also dg'd to Hold at Stifel TWGP -3.1%, SDRL -1.7%.

Select metals/mining stocks trading lower: DRD -5.6%, GDX -2.4%, AU -2.3%, ABX -1.8%, KGC -1.7%, AEM -1.7%, GG -1.6%, NEM -1.4%, IAG -1.4%, HMY -1.3%, GLD -1.2%, SLV -1%, MT -0.8%.

Other news: UNXL -20.3% (disclosed that it learned that the Fort Worth Regional Office of the SEC has issued subpoenas concerning the Company's agreements related to its InTouch Sensors), CLDX -9.3% (demonstrates promising clinical activity in patients with EGFRvIII-positive recurrent glioblastoma), XCO -2.1% (announces intent to conduct rights offering; if all of the rights are exercised, the co would raise ~ $272.9 mln), STO -1.4% (in sympathy with SDRL), QCOM -1.3% (China's National Development and Reform Commission has commenced an investigation of Qualcomm relating to the Chinese Anti-Monopoly Law).

Analyst comments: CLX -2.3% (downgraded to Sell from Neutral at Goldman), CPB -2.2% (downgraded to Neutral from Buy at Goldman), JBLU -1.5% (downgraded to Underperform from Mkt Perform at Raymond James), AOL -1.5% (downgraded to Sector Perform at RBC Capital Mkts).

Early premarket gappers

Gapping up: OREX +30.0% GA +15%, ARIA +11.9%, GLUU +8.2%, FMS +8%, VJET +5.9%, SIRI +4.3%, NXTM +3.6%, DVA +3.1%, ANIK +3%, STML +2.9%, BBY +2.4%, RPRX +2.1%, MSFT +0.6%.

Gapping down: UNXL -21.5%, DRD -5.6%, QIHU -4.7%, KGC -2.6%, AU -2.4%, SDRL -1.7%, JCP -1.6%, ABX -1.2%, GDX -1.2%, HMY -1%, SLV -0.9%, GLD -0.9%, MT -0.9%, NEM -0.8%, CLDX -0.7%, AEM -0.7%.

Sanofi looking at 1-2 billion euros in acquisitions per year - CEO

(Reuters) - French drugmaker Sanofi (SASY.PA) plans to spend 1 to 2 billion euros ($1.4-2.7 billion) each year on acquisitions, its chief executive, Chris Viehbacher, told Le Figaro newspaper.

Since taking the helm five years ago, Viehbacher has sought to refill Sanofi's drug pipeline, spending 24 billion euros on acquisitions - including on the takeover of U.S. biotech firm Genzyme - to offset the loss of patents on top-selling drugs.

In an interview with Le Figaro, Viehbacher said Sanofi had got over the worst of its "patent cliff" in September and that sales were growing again, driven by the company's seven priority platforms: diabetes, vaccines, emerging markets, automedication, animal health, rare diseases and "other innovative products."

"I'm satisfied with Sanofi's current perimeter," Viehbacher said. "We will keep reinforcing the growth platforms, to the tune of 1 to 2 billion euros per year in acquisitions. But I don't think we should widen this perimeter."

Last month, Sanofi lowered its full-year profit guidance for a second time after a slowdown in China, weaker generic sales in Brazil and manufacturing problems at a Toronto vaccine plant dented third-quarter results.